LobbyingAmericans for Homeopathy Choice Action lobbying by quarter
Americans for Homeopathy Choice Action's latest lobbying report covers Q2 2026, at $60K. The four quarters Q4 2025–Q3 2026 total $180K. Its first report covers Q1 2023; the issues it reports most are Health Issues.
Americans for Homeopathy Choice Action
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $180K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2023 | $30K | 1 |
| Q2 2023 | $30K | 1 |
| Q3 2023 | $30K | 1 |
| Q4 2023 | $10K | 1 |
| Q1 2024 | $10K | 1 |
| Q2 2024 | $16K | 1 |
| Q3 2024 | $6,900 | 1 |
| Q4 2024 | $50K | 2 |
| Q1 2025 | $60K | 2 |
| Q2 2025 | $60K | 2 |
| Q3 2025 | $60K | 2 |
| Q4 2025 | $60K | 2 |
| Q1 2026 | $60K | 2 |
| Q2 2026 | $60K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$542.9K · 21 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES21 reports
- SENATE21 reports
- Food & Drug Administration (FDA)5 reports
Firms it paid
| Firm | ||
|---|---|---|
| Venable | $340K | 7 quarters |
| In-houseAmericans for Homeopathy Choice Action | $202.9K | 14 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | In-house | $10K |
| 07/17for Q2 | Venable | $50K |
| 04/20for Q1 | In-house | $10K |
| 04/15for Q1 | Venable | $50K |
| 01/20for Q4 2025 | In-house | $10K |
| 01/13for Q4 2025 | Venable | $50K |
| 25/10/16for Q3 2025 | In-house | $10K |
| 25/10/16for Q3 2025 | Venable | $50K |
| 25/07/18for Q2 2025 | In-house | $10K |
| 25/07/15for Q2 2025 | Venable | $50K |
| 25/04/14for Q1 2025 | Venable | $50K |
| 25/04/10for Q1 2025 | In-house | $10K |
| 25/01/22for Q4 2024 | Venable | $40K |
| 25/01/21for Q4 2024 | Venable | Under $5,000 |
| 25/01/19for Q4 2024 | In-house | $10K |
| 24/10/18for Q3 2024 | In-house | $6,900 |
| 24/07/19for Q2 2024 | In-house | $16K |
| 24/04/20for Q1 2024 | In-house | $10K |
| 24/01/19for Q4 2023 | In-house | $10K |
| 23/10/20for Q3 2023 | In-house | $30K |